Trace Neuroscience, which launched this week with $101 million, benefited from last year’s approval of Qalsody. Its CEO spoke ...
Many companies just iterate indefinitely without ever making progress toward an actual drug,” said one biotech VC on a panel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback